Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor
- PMID: 18059341
- DOI: 10.1038/sj.onc.1210957
Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor
Abstract
The Raf-mitogen-activated protein kinase (MAPK) and phosphatidylinositide 3-kinase (PI3K)-AKT pathways are two downstream effectors of the small GTPase Ras. Although both pathways are positively regulated by Ras, the Raf-MAPK and PI3K-AKT pathways have been shown to control opposing functions within the cell, suggesting a need for cross-talk regulation. The PI3K-AKT pathway can inhibit the Raf-MAPK pathway directly during processes such as muscle differentiation. Here we describe the ability of the Raf-MAPK pathway to negatively regulate the PI3K-AKT pathway during cellular arrest. Constitutive activation of Raf or methyl ethyl ketone 1 (MEK1) leads to inhibition of AKT and cellular arrest. Furthermore, we show that activation of Raf-MEK1 signaling causes negative feedback inhibition of Ras through the ephrin receptor EphA2. EphA2-mediated negative feedback inhibition is required for Raf-induced AKT inhibition and cell cycle arrest, therefore establishing the inhibition of the Ras-PI3K-AKT pathway as a necessary event for the Raf-MEK1-regulated cellular arrest.
Similar articles
-
Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma.Cancer. 2010 Jun 15;116(12):2974-83. doi: 10.1002/cncr.25061. Cancer. 2010. PMID: 20564403
-
Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells.Mol Cancer Res. 2003 Dec;1(14):1077-88. Mol Cancer Res. 2003. PMID: 14707291
-
Thrombopoietin (TPO) induces c-myc expression through a PI3K- and MAPK-dependent pathway that is not mediated by Akt, PKCzeta or mTOR in TPO-dependent cell lines and primary megakaryocytes.Cell Signal. 2006 Aug;18(8):1212-8. doi: 10.1016/j.cellsig.2005.09.010. Epub 2005 Dec 27. Cell Signal. 2006. PMID: 16380230
-
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review).Int J Oncol. 2003 Mar;22(3):469-80. Int J Oncol. 2003. PMID: 12579299 Review.
-
Raf: a strategic target for therapeutic development against cancer.J Clin Oncol. 2005 Sep 20;23(27):6771-90. doi: 10.1200/JCO.2005.08.036. J Clin Oncol. 2005. PMID: 16170185 Review.
Cited by
-
Generation of dopamine neurons with improved cell survival and phenotype maintenance using a degradation-resistant nurr1 mutant.Stem Cells. 2009 Sep;27(9):2238-46. doi: 10.1002/stem.146. Stem Cells. 2009. PMID: 19522012 Free PMC article.
-
Eph receptor signaling and ephrins.Cold Spring Harb Perspect Biol. 2013 Sep 1;5(9):a009159. doi: 10.1101/cshperspect.a009159. Cold Spring Harb Perspect Biol. 2013. PMID: 24003208 Free PMC article. Review.
-
Eph receptors and ephrins in cancer: bidirectional signalling and beyond.Nat Rev Cancer. 2010 Mar;10(3):165-80. doi: 10.1038/nrc2806. Nat Rev Cancer. 2010. PMID: 20179713 Free PMC article. Review.
-
Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.J Oncol. 2009;2009:951917. doi: 10.1155/2009/951917. Epub 2010 Jan 14. J Oncol. 2009. PMID: 20130824 Free PMC article.
-
Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Expert Opin Ther Targets. 2011 Jan;15(1):31-51. doi: 10.1517/14728222.2011.538682. Expert Opin Ther Targets. 2011. PMID: 21142802 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous